Shanghai’s I-Mab Biopharma announced that its novel CD73 antibody (TJD5), an immunotherapy, was cleared to start Phase I trials in the US. TJD5, the second I-Mab candidate to begin US clinical trials, will be tested in patients with advanced solid tumors. The IND application was filed by I-Mab’s US partner, Tracon Pharma of San Diego. In November 2018, the two companies agreed to share US development costs of I-Mab’s TJD5 and up to five unspecified bi-specific candidates.
Source: China Biotoday
